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Abstract: The implementation of nanotechnology in medicine has opened new research
horizons particularly in the ﬁeld of therapeutic delivery. Mesoporous silica particles have
emerged as biocompatible drug delivery systems with an enormous potential in the treatment
of cancer among many other pathologies. In this review, we focus on the unique properties of
these particles as chemotherapy delivery carriers. Here, we summarize the general character-
istics of these nanomaterials – including their physicochemical properties and customizable
surfaces – different stimuli that can be used to trigger targeted drug release, biocompatibility
and ﬁnally, the drawbacks of these types of nanomaterials, highlighting some of the most
important features of mesoporous silica nanoparticles in drug delivery.
Keywords: nanocarrier, drug release, targeted drug delivery, biocompatibility,
biodegradability, tumor
Introduction
Chemotherapy, tog ether with surgery, are the most used cancer treatments in
oncology. Unfortunately, chemotherapeutic agents are applied systemically destroy-
ing both tumor and healthy cells and resulting in many of undesirable side effects.1
Encapsulated drug delivery systems offer the possibility to target therapies locally
at adequate concentrations, maximizing the effect against cancer cells while redu-
cing the side effects and cytotoxicity in healthy cells.2 In this sense, nanotechnology
can help with the design of target-speciﬁc and controlled delivery systems, capable
of transporting enough therapies to speciﬁc cells, releasing the drug in a controlled
manner.2
Different types of nanomaterials have been used as targeted carriers. Among
others, the most employed are liposomes,3,4 polymeric micelles,5,6 carbon
nanotubes,7 dendrimers,8–10 inorganic particles11 and silica-based materials12,13
(Figure 1). Recently, mesoporous silica particles (MSPs) have attracted much
attention due to their singular properties.14 Here we discuss some of their char-
acteristics and advantages in cancer drug delivery.15
Physicochemical properties of MSPs
MSPs have a well-deﬁned internal mesopore structure (from 2 to 10 nm of diameter)
with a large pore volume (0.6−1 cm3/g) and a high surface area (700−1,000 m2/g).
Their size, nano- (50 nm) to submicron-scale (500 nm),16 as well as their shape17 and
surface18 can be custom-designed offering many different possibilities for the loading
of anticancer drugs such as docetaxel,19 paclitaxel20 or doxorubicin,21 among many
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others. Moreover, the cytotoxicity of these particles and
cellular uptake have been demonstrated to be dependent on
nanoparticle size and surface charge. Indeed, 15 nm diameter
particles have been reported to trigger more cytotoxicity than
100 nm diameter particles in endothelial cells.22 Lu and
collaborators showed that 50 nm diameter particles are the
optimal for cellular uptake.23 When considering the particle
surface charge, cationic silica particles appear to be more
cytotoxic and have a faster cellular uptake than anionic or
neutral silica particles.24,25 Davila-Ibáñez and co-workers
used magnetic silica nanoparticles with DNA attached to
the silica network to show how charges at the surface of the
nanoparticles is a key issue to guarantee the cellular
uptake.26,27 On the other hand, particles with a neutral charge
do not appear to internalize the cell membrane of Caco-2
cells.
Targeting the cell/tissue of interest
One of the most important goals to achieve in drug deliv-
ery is the possibility of targeting nanoparticles to a speciﬁc
cell or tissue. In this regard, most nanomaterials including
MSPs, have been reported to passively target solid tumors.
Typically, when a tumor reaches a certain size, the normal
vasculature present in the tumoral organ cannot irrigate all
the cellular mass. This effect generates intra-tumoral
hypoxia triggering the segregation of growth factors that
activate the rapid sprouting of new blood vessels from the
surrounding capillaries.28 This process known as angio-
genesis generates irregular blood vessels displaying
a discontinuous epithelium with an absent basal
membrane.29 When blood components reach these abnor-
mal and discontinuous vascular networks, the fenestrations
between the endothelial cells offer little resistance to the
extravasation of nanomaterials inside of the tumor.30
Particles/molecules smaller than 4 nm diffuse through the
capillary endothelium back to the blood circulation and are
reabsorbed,31 but macromolecules and nanomaterials do
not naturally return to the blood vessels, accumulating in
the perivascular tumoral space. In the nanomedicine ﬁeld,
this phenomenon is known as the Enhanced Permeability
and Retention effect or “EPR” effect (Figure 2). The study
carried out by Lee and co-workers, showed how MSPs
decorated with multiple magnetite nanocrystals loaded
with Doxorubicin (DOX), induced efﬁcient cell death in
a melanoma model, conﬁrming in vivo passive targeting
and accumulation of the nanoparticles in the tumor site.32
Huan and colleagues used MSPs functionalized with poly-
ethyleneimine/polyethylene glycol (PEI/PEG) to carry
doxorubicin together with P-glycoprotein siRNA. Their
study demonstrated that these particles were effectively
biodistributed, achieving an 8% of the enhanced perme-
ability and retention effect at the tumor site in vivo.33 But
there are many more examples in the literature.
MSPs can also be functionalized to actively target
tumors. One of the strategies used to reach this goal consists
in the attachment of different ligand molecules – such as
peptides, antibodies,34 aptamers,35 growth factors,36 vita-
mins, etc. – on their surface, so the particles interact with
receptors on the cellular surface (Figure 3).37 This way, the
entry mechanism of the nanodevice will be via receptor-
mediated endocytosis, and the particle will be captured inside
the endosomal membranes.37 In the study carried out by
Kayuan and colleagues, HB5 aptamer-functionalized meso-
porous silica-carbon-based DOX-loaded systems (MSCN-
PEG-HB5/DOX) were used in vitro for chemo-
photothermal combined therapy in Human Epithelial growth
factor Receptor 2 (HER2)-positive breast cancer cells. This
study demonstrated how HER2-positive breast cancer cells
uptake these particles with more avidity than normal breast
epithelial cells (MCF-10A). Additionally, cytotoxicity
experiments demonstrated that combined therapy induces
highest cell killing effect compared to chemotherapy and
photothermal therapy by itself.38 Jianbin and colleagues
showed how MSPs of 40 nm size, loaded with DOX and
functionalized with selective αv-β3 integrin ligands on their
surface displayed an enhanced targeting effect through the
Figure 1 Schematic representation of different delivery systems. From left to right; liposomes, micelles, carbon nanotubes, dendrimer and gold (yellow) and iron (brown)
nanoparticles.
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blood–brain barrier, penetrating glioblastoma cells. In sum-
mary, these targeted particles rapidly invaded cancer cells,
delivering the drug intracellularly and improving the antic-
ancer activity of the free drug. MSPs achieve satisfactory
anti-glioblastoma efﬁcacy avoiding toxic side effects in the
healthy brain tissue thus, demonstrating active cell
targeting.39
Controlling drug release: gatekeepers
Another challenge in the design of nanotransporters is
delivering the drug at the precise moment when the carrier
reaches the tumor, or alternatively, when a signal is pro-
vided. MSPs are useful carrier systems due to their high
surface and tunable porous structure. Drugs can be loaded
inside their mesopores through simple diffusion mechan-
ism. But, one of the main advantages of MSPs is the
possibility to design “zero release” nanosystems by block-
ing the MSP pores using gatekeepers.13,40
Once in the tumor, different internal or external stimuli
can be employed to activate drug delivery. Some of the
intra-tumoral stimuli used are the local pH conditions, the
enzymes in the peritumoral tissue or the redox potential. In
Normal tissue Tumor tissue
Blood
vessel
Small molecules
Nanoparticles
Figure 2 Image representing the blood transport mechanism of nanomaterials or molecules from normal tissue (left) and the enhanced permeability and retention effect in
a tumor.
Antibodies
Proteins
Aptamers
Vitamins
Peptides
Figure 3 Schematic description of active targeting possibilities on mesoporous silica particles (left). Dual targeting example (right).
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addition, external stimuli such as magnetic ﬁelds or light
can also be applied to activate “on demand” drug release
(Table 1, Figure 4).
Internal stimuli triggering drug delivery
The characteristics of the tumoral environment can help in
the design of nanocarriers sensitive to internal or endogen-
ous stimuli to ensure a controlled localized drug release.
● pH-sensitive systems
One general feature of solid tumors is the presence of
acidity in the tumor environment due to the “Warburg effect”.
Healthy cells use the mitochondrial oxidative phosphorylation
to produce energy. However, most cancer cells activate the
glycolytic route.41,42 This process, also known as anaerobic
glycolysis, is less efﬁcient in terms of energy (adenosine
triphosphate) production and increases the generation of addi-
tional metabolites – mostly lactic acid – generating local
tumoral acidosis which can be beneﬁcial for tumor proliferat-
ing cells.41,42
An effective strategy to control drug release is blocking the
MSP pores with noncovalently bonded pH sensible polymers.
Different polymers can be selected so they detach from the
particle at low pH, releasing the drug at the tumoral site.
Among these systems, one of the most commonly used meth-
ods is based on polyelectrolyte multilayers. These gatekeepers
are based on the layer-by-layer technique (Figure 5).43–45 The
Table 1 Different gatekeepers that can be used to maintain the “zero release” of the drug and to trigger drug release
External stimuli Internal stimuli
Magnetic ﬁeld Light pH Sensitive
systems
Redox sensitive
systems
Enzyme sensitive
systems
Magnetic
particles
Magnetic
nanocrystal
Gold nano-
particles
Photolabile
molecules
Polyelectrolytes Ester
bond
Acetal
bond
Peptides Disulfude bond
External stimuli
Internal stimuli
M
agnetic particles
Magnetic nanocrystals
Disulfide bond
Enzyme sensitive system R
edo
x s
ens
itiv
e s
yst
em
pH sensitive system
Light
M
agnetic fields
Pe
ptid
es
Acetal bond
Ester bond
Polyelectrolytes
Gold particles
Ph
oto
lab
ile 
mo
lec
ule
s
Figure 4 Examples of different gatekeepers that can be used to maintain the “zero release” of the drug inside mesoporous silica particles and to trigger on demand the
release.
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composition, thickness or the molecular organization of the
layers46 and the permeability/elasticity of the polymers can be
modiﬁed so the system can be easily “tuned”.47 Feng et al
synthesizedMSPs coated with multilayers of Poly(Allylamine
Hydrochloride) (PAH) and Poly(Styrene Sulfonate) (PSS)
polyelectrolytes, loaded with DOX inside the pores.48 In this
study, they demonstrated that the delivery of the drug was both
pH and layer thickness dependent, and that the layer thickness
has an exponential relationship with the number of polymer
coats applied. This study also demonstrated that i) the biodis-
tribution of the drug in vivo was smaller in major organs
compared to that of free DOX, and that ii) these particles
had lower systemic toxicity than free DOX, thus, concluding
that these MSP-based nanoparticles were a good carrier sys-
tem with high efﬁciency and low systemic toxicity. Also, Sun
et al used multilayer-coated MSPs to load cisplatin and
Rhodamine B (RhB).49 The outer polyelectrolyte multilayer
was assembled from the cationic polyelectrolyte PAH, and
a second negatively charged polyelectrolyte, P(DMA-co-
TPAMA), consisting of N,N-Dimethylacrylamide (DMA)
and 3,4,5,6-Tetrahydrophthalic Anhydride functionalized
N-(3-Aminopropyl) Methacrylamide (TPAMA) monomer
units, that exhibited pH-induced charge conversion character-
istics. This way, cisplatin and rhodamine B were released in
the tumor microenvironment upon a pH reduction from 7.4 to
5–6, typical in malignant tumors. Other interesting gatekeeper
systems are based on pH-sensitive linkers. These linkers are
cleaved in acidic conditions, triggering the release of the cargo
from the carrier. Acetal bonds,50–52 hydrazine bonds,53–55
hydrazone bonds56,57 or ester bonds58,59 are some examples
that have been used worldwide. In a study carried out by Ze-
Yong Li et al, DOX was conjugated to MSPs using hydrazine
bonds.60 They proved that when the particles were in vitro
incubated at pH 6.5, a fast DOX release occurred due to the
hydrolysis of the bonds. Lee et al were able to attach DOX to
the inner wall of MSPs and release this drug in the endolyso-
somes of cancer cells in the liver.61 The conjugation of the
drugwas done by hydrazone bonds that released the drug upon
endo-lysosomal maturation when the pH of the vesicles
decreased.
● Enzyme-responsive systems
Compared to healthy tissues or cells, many different
enzymes, mostly proteases, are overexpressed by cancer
cells.62 This peculiarity can also be an interesting stimulus
to trigger enzyme-mediated drug release.63 The develop-
ment of enzyme-released drug delivery systems based on
MSPs has caught much attention. Liu et al used in their
study a Matrix-Metalloproteinase (MMPs) responsive drug
delivery system based on MSPs to reduce in vivo side
effects of traditional chemotherapies.64 MSPs were loaded
with DOX and coated with bovine serum albumin as an
end-cap to seal the mesopores of the nanoparticles, using
lactobionic acid as the targeting motif. The in vivo experi-
ments showed that the DOX delivery system could be used
to inhibit tumoral growth in mice with minimal side
effects.
● Redox-sensitive systems
Glutathione (GSH) is the most abundant non-
protein thiol that acts as a reducing agent maintaining
enzymes in an active state. In cancer cells, the intra-
cellular concentration of GSH is three times higher
than in normal cells.65 Hence, this is a good tool to
prompt the release of drugs. Disulﬁde bonds66-70 (S-S)
can be easily cleaved in the presence of GSH for being
a redox-sensitive group, so they can be used to form
capped systems with nanoparticles71,72 or
polymers69,73,74 for instance. Gong et al were able to
synthesize MSPs functionalized with polyethylene gly-
col using a disulﬁde bond linker.74 These authors
demonstrate drug release upon GSH rise, while low
GSH concentrations blocked the release. Apart from
PEG,75,76 poly N-acryloxysuccinimide77 has also been
Step 1 Step 2 Step 3 Step 4
Figure 5 Scheme of the layer by layer technique in mesoporous silica particles.
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used as an efﬁcient method to deliver hydrophilic
drugs to cancer cells improving the efﬁcacy of the
therapy.
External stimuli for drug delivery
Magnetic ﬁelds and light are external stimuli also used to
control gatekeepers. Although these stimuli are less popular
than endogenous stimuli, they are more reproducible and do
not depend on the heterogeneous physiological conditions
of the tumoral environment. Besides, these systems can be
more precise in local drug release, minimizing toxicity and
side effects.78 The two main strategies of these drug deliv-
ery systems are based on magnetic ﬁelds and light.
● Magnetic ﬁelds
These drug delivery systems are based on the use of
magnetic ﬁelds as external stimuli to guide the particles to
the tumor environment and to locally increase the tem-
perature, triggering cell death by controlled drug release
and/or hyperthermia.79 Superparamagnetic iron oxide
nanoparticles are the most used magnetic nanoparticles.
They exhibit an extraordinary capacity to convert mag-
netic energy into heat.80,81 This ability allows the use of
thermo-sensitive materials as gatekeepers capping the sur-
face of MSPs, provoking the opening of the pores and the
release of a drug using magnetic ﬁelds.82,83 Baeza and
colleagues used a nanodevice based on MSPs with iron
oxide nanocrystals inside the silica matrix.83 This device
was coated with a copolymer of Poly(Ethyleneimine)-
b-Poly (N Isopropylacrylamide) (PEI/NIPAM), which
acts as a temperature-sensitive gatekeeper and retains pro-
teins into the polymer shell linked by electrostatic forces
or hydrogen bonds. Once these nanodevices are admini-
strated into cancer cells, an alternative magnetic ﬁeld is
applied. The results demonstrate that the polymer can act
as a gatekeeper, opening or closing the pores of the silica
matrix, controlling the release of the macromolecules
attached to the polymer branches. Moreover, Thomas
et al used in their study DOX-loaded MSPs combined
with magnetic nanocrystals that have been surface-
modiﬁed with pseudorotaxanes.84 After the application of
a magnetic ﬁeld, the nanocrystals generate heat, causing
the disassembly of the pseudorotaxanes, triggering the
release of DOX and consequently, a cytotoxic effect in
breast cancer cells.
● Light
Among the external stimulus, light is a rapid, non-
invasive, clean and efﬁcient stimulus that can be used to
control drug delivery with high spatial and temporal
resolution.85,86 Although most photoreactions used in
drug delivery are induced by UV light,85,87,88 the best
wavelengths for good tissue penetration are those in the
close IR, between 800 and 1,100 nm, which correspond to
the so-called “water biological window”.89 The mechan-
ism of these types of carriers to trigger drug release is
based on the photo-sensitiveness of the gatekeeper that
changes conformation upon light application. Guardado-
Alvarez et al used MSPs with photolabile coumarin-based
molecules capping the surface, noncovalently conjugated
β-cyclodextrin to block the pores and rhodamine B inside
the pores.90 This way, 800-nm two-photon excitation trig-
gered the release of the bond holding the coumarin to the
nanopore releasing both the β-cyclodextrin cap and the
cargo. Martínez-Carmona and colleagues carried another
study in vitro using an MSP-based device with porphyrin-
caps attached with reactive oxygen species (ROS)-
cleavable linkages.91 These bonds are sensitive to singlet-
oxygen produced after exposure to visible light, releasing
the cargo (Topotecan). The oxygen molecules produced by
the porphyrin–nanocaps break the sensitive-linker uncap-
ping the pores and releasing the entrapped drug. These
particles have been used in osteosarcoma cancer cells
demonstrating a controlled release of Topotecan inside
the tumor cells. Another light-sensitive gatekeeper type is
based on gold nanoparticles (AuNPs). These particles,
combined with MSPs, are attractive devices for cancer
cell imaging92-94 and can also heat when irradiated with
a laser producing a photothermal effect.93 As for the
magnetic nanoparticles, the heat generated upon light
exposure can be used to release the anti-cancer therapy
and/or trigger drug release. Wang and colleagues, for
instance, designed a therapeutic delivery system, based
on MSPs closed by AuNPs with RhB as the cargo.95
This carrier was studied in vitro showing a good release
of the RhB when temperature increased. In the study done
by Vivero-Escoto et al AuNP-capped-MSPs were useful to
release a chemotherapeutic such as paclitaxel in human
ﬁbroblast and liver cells.96 This release could be easily
controlled by low-power photoirradiation under physiolo-
gical conditions.
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Concerning the use of internal and external stimuli, it is
important to mention the combination of both types of
stimuli, light and alternating magnetic ﬁelds, to generate
heat, to induce local hyperthermia increasing the pH97 and
the enzymatic activity98 of the cells. Hence, this type of
structured nanomaterials can be used as an interesting
system for programmed site-speciﬁc drug delivery.
Triggering endolysosomal escape
Upon receptor-mediated endocytosis, MSPs are incorporated
inside the endolysosomal membranes. Many nanoparticles
after intracellular transit are eventually expelled from the
cells by exocytosis.99–101 Thus, to avoid therapy degradation
in the lysosomal due to the hostile chemical conditions and/
or, exocytosis, nanocarriers need to escape into the cyto-
plasm. Thus far, different strategies have been developed to
trigger lysosomal escape among these, the proton sponge
effect102 and destabilization of the endosomal membrane
are the most used.103 The ﬁrst mechanism is based on the
swelling of the vesicle, and the second, in the creation of
pores that enable therapeutic release into the cytoplasm.
The proton sponge effect
This effect relies on the rise of the proton concentration during
hydrolysis that, in turn, causes an increase in the membrane
potential, osmotic swelling and ﬁnally endo-lysosome
bursting.104 This phenomenon occurs when polyplexes such
as PEI or PAMAM are endocytosed. The amine groups of
these molecules capture protons that accumulate in endo-
somes, gradually increasing the membrane potential and
breaking the lysosomal membrane equilibrium. The diffusion
of Cl− molecules into endosomes cause the increase of the
osmotic pressure, swelling, expanding and ﬁnally tearing the
lipid bilayer of the endolysosome, releasing the contents into
the cytoplasm (Figure 6).102 TheMSPs used byWu et al could
release siRNA and DOX into the cytoplasm of breast cancer
cells in vitro and in vivo using a Poly-β-amino ester coating to
provoke endolysosome bursting.105 The work carried out by
Shen et al demonstrated that MSPs coated with PEI cannot
only carry a siRNA but also deliver it to xenografted tumors,
reducing the size of the tumoral mass.106
Destabilization of the endosomal membrane
Other mechanisms to trigger particle endo-lysosomal escape
are fusion lipids, cationic polymers, peptides107 or carbon
nanotubes.103 In the study performed by Zhang et al, they
synthesized polymer-lipid supported mesoporous silica
nanoparticles (PLS-MSPs).108 These nanocarriers were able
to release the anticancer drug (CPT -11) and maximize the
effect of the treatment in MDR breast cancer cells. Apart
from fusion lipids, many cell-penetrating peptides (fusogenic
peptides) are being used based on bacterial or viral proteins.
These peptides trigger vacuole-based endocytosis and/or to
create discontinuities or pores on the cell membrane.109,110
For instance, Li and colleagues used MSPs coated with PEI
and a fusogenic peptide to deliver siRNA to a tumor model
showing an inhibition of the tumoral cell proliferation.111
Likewise, in some of our studies, we show how silica nano-
particles, when coated with multi-walled carbon nanotubes
(MWCNT), can escape the endo-lysosomal route mimicking
the viral spike fusion in lysosomes. The hypothesis is that
proteins functionalizing theMWCNTsurface are degraded in
endolysosomes, exposing the surface of the nanotubes that
are highly reactive and apolar. These stripped ﬁlaments now
interact with the membrane of the endo-lysosomal vesicles,
piercing and tearing it apart, triggering particle release into
the cytoplasm (Figure 7).103
Biocompatibility
Last, but not least, one of the most important features of MSPs
is their biocompatibility. Different studies have demonstrated
that silica nanoparticles are not toxic when administrated to
different cell types at different dosages.99,112–114 Furthermore,
there are several reports demonstrating that MSPs are degrad-
able in water and in phosphate buffer saline.13,14 There are
different parameters that can triggerMSPs in vitro degradation
including i) particle morphology,115 ii) surface area116 and iii)
surface functionalization117,118 among others. For instance,
spherical particles are more degradable than with rod-shaped
particles.115 Similarly, particles that have a high surface area
are more degradable.116 Interestingly, the MSPs size is appar-
ently not all that important in degradation in water or simu-
lated body ﬂuids.119,120 Moreover, MSP and their fragments
have also been reported to be eliminated by renal clearance, in
urine, and/or feces.113,121,122 Interestingly, positively charged
MSPs are cleared faster than particles with a negative ζ poten-
tial. Also, PEGylated MSPs show a higher in vivo circulation
time, since PEG avoids macrophage recognition and phago-
cytosis in the liver and spleen. Other studies are now devel-
oping to improve the interactions of nanomaterials with blood
components. For instance, Roggers et al have demonstrated
that the functionalization of MSPs with different lipids can be
used to imitate red blood cell lipid membranes, improving
their hemo-biocompatibility.121
Dovepress Iturrioz-Rodríguez et al
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Drawbacks of MSPs
Ideally, nanoparticles need i) to be stable, ii) to have
a high loading capacity, iii) to be reproducible and iv)
scalable in production. Reproducible MSPs synthesis is
reasonably feasible when working at small scale, but the
scaling up is not trivial therefore, reproducibility at
industrial scale must be critically considered. Regarding
the loading capacity of MSPs, not all drugs can be incor-
porated at an adequate concentration, and this critically
inﬂuences the total concentration of nanoparticles that
should be administrated to obtain an effective therapeutic
effect. For instance, the tolerated dose of uncoated MSPs
in murine models is ca. 50 mg/kg, but the human toler-
ance is so far unknown and needs to be evaluated.122
Also, most biodistribution and excretion studies have
been performed in mice123 and must be reproduced in
humans to understand the immune response and possible
side-effects of these nanomaterials.
Another important point regarding the use of MSPs in
clinical trials is the fact that the Food and Drug
Administration and the European Medicines Agency
must evaluate drug delivery nanocarriers before bench-to-
bed translation, even if loaded with drugs already
approved for clinical use. This is a slow procedure that
signiﬁcantly delays all new developments in nanodelivery.
Hopefully, soon new requirements will be developed to
accelerate the translation from research to the clinic.
Conclusion
The ﬁeld of nanotechnology is gaining a high interest in
cancer medicine. MSPs can be customized on demand in
order to engineer nanocarriers that can i) target cells spe-
ciﬁcally, ii) release drugs inside the desired tissues/cells
reducing the side effects of the treatment, iii) invade the
cytoplasm by scaping the endo-lysosomal membrane, so
that the cargo is preserved and ﬁnally iv) be biodegraded
Nucleus
Endosome
Lysosome
H2O
H+
Cl-
ATPase
Chloride channel
H2O
Lysosomal rupture
PEI-MSN
Figure 6 Diagram of the proton sponge effect: particles coated with polyethyleneimine (PEI) are captured in the endolysosomal route. Lysosomal membranes tear apart,
releasing the particles in the cytosol.
Abbreviation: PEI-MSN, mesoporous silica particles coated with PEI.
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or cleared from the organism to minimize toxicity.
Although MSPs are being widely studied as nanocarrier
systems in animal models to ensure they are safe, more
research is needed in the ﬁeld of nanodelivery in cancer.
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